We are live on ! Find out more
LABD icon

Direxion Daily S&P Biotech Bear 3X ETF
LABD

18 hedge funds and large institutions have $23.1M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

173% more capital invested

Capital invested by funds: $8.45M → $23.1M (+$14.7M)

38% more funds holding

Funds holding: 13 → 18 (+5)

11.91% more ownership

Funds ownership: 3.78% → 15.69% (+12%)

46% less call options, than puts

Call options by funds: $824K | Put options by funds: $1.54M

Holders
18
Holders Change
+5
Holders Change %
+38.46%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
2
Closed
–
Calls
$824K
Puts
$1.54M
Net Calls
-$712K
Net Calls Change
-$2.17M

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$17.3M
2
SG Americas Securities
SG Americas Securities
New York
+$2.88M
3
VF
Virtu Financial
New York
+$2.15M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.04M
5
TSS
Two Sigma Securities
New York
+$519K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$557K
2
Jane Street
Jane Street
New York
-$38.4K

LABD Hedge Fund Activity: Q2 2017 in Review

18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2017, worth a combined $23.1M — up 173% from $8.45M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new LABD positions and 0 closed out — a net gain of 5 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $17.3M. The largest seller was Citadel Advisors, cutting an estimated $557K.

  • 18 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2017, up from 13 in Q1 2017.
  • Funds reported $23.1M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2017, up 173% quarter-over-quarter.
  • 5 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2017 and 0 closed out, a net change of +5 holders.
  • The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2017 was Citigroup, an estimated $17.3M added.
  • The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2017 was Citadel Advisors, an estimated $557K sold.

Based on aggregated 13F filings for Q2 2017.